Cargando…
Design of Novel Phosphatidylinositol 3-Kinase Inhibitors for Non-Hodgkin’s Lymphoma: Molecular Docking, Molecular Dynamics, and Density Functional Theory Studies on Gold Nanoparticles
Non-Hodgkin’s lymphomas are a diverse collection of lymphoproliferative cancers that are much less predictable than Hodgkin’s lymphomas with a far greater tendency to metastasize to extranodal sites. A quarter of non-Hodgkin’s lymphoma cases develop at extranodal sites and the majority of them invol...
Autores principales: | Ali, Abdalrahim M., Makki, Alaa A., Ibraheem, Walaa, Abdelrahman, Mohammed, Osman, Wadah, Sherif, Asmaa E., Ashour, Ahmed, Ibrahim, Sabrin R. M., Ghazawi, Kholoud F., Samman, Waad A., Alzain, Abdulrahim A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10005307/ https://www.ncbi.nlm.nih.gov/pubmed/36903539 http://dx.doi.org/10.3390/molecules28052289 |
Ejemplares similares
-
Design of Novel Letrozole Analogues Targeting Aromatase for Breast Cancer: Molecular Docking, Molecular Dynamics, and Theoretical Studies on Gold Nanoparticles
por: Edris, Alaa, et al.
Publicado: (2023) -
Computational Insights into Natural Antischistosomal Metabolites as SmHDAC8 Inhibitors: Molecular Docking, ADMET Profiling, and Molecular Dynamics Simulation
por: Alzain, Abdulrahim A., et al.
Publicado: (2023) -
Unlocking the potential of approved drugs for the allosteric inhibition of tropomyosin-receptor kinase A using molecular docking and molecular dynamics studies
por: Mukhtar, Rua M., et al.
Publicado: (2023) -
Exploring the potential of approved drugs for triple-negative breast cancer treatment by targeting casein kinase 2: Insights from computational studies
por: Shoaib, Tagyedeen H., et al.
Publicado: (2023) -
Drug repurposing against main protease and RNA-dependent RNA polymerase of SARS-CoV-2 using molecular docking, MM-GBSA calculations and molecular dynamics
por: Mohammed, Ahmed O., et al.
Publicado: (2022)